Global asthma market to hit $18 billion by 2021 boosted by biologics – The Pharma Letter


The Pharma Letter

Global asthma market to hit $18 billion by 2021 boosted by biologics
The Pharma Letter
Natasha Spiller, an analyst at Datamonitor Healthcare said: “Severe asthma remains a significant cause of mortality and morbidity and a portion of patients remain inadequately treated, despite the use of inhaled corticosteroids and long-acting beta 2

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.